Comparative Pharmacology
Head-to-head clinical analysis: CROMOLYN SODIUM versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CROMOLYN SODIUM versus KETOTIFEN FUMARATE.
CROMOLYN SODIUM vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes mast cell membranes, inhibiting release of histamine and other mediators of inflammation.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
For bronchial asthma: 20 mg (2 capsules) orally 4 times daily, administered 1 hour before meals and at bedtime. For allergic rhinitis: 1 spray (5.2 mg) in each nostril 3-6 times daily. For mastocytosis: 200 mg orally 4 times daily.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours for the absorbed fraction; the short half-life necessitates frequent dosing (e.g., 4 times daily) for sustained clinical effect.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily excreted unchanged in bile and feces (approximately 98% after oral administration); renal excretion is minimal (<1% unchanged in urine). After inhalation, a small amount is absorbed systemically and similarly excreted via bile/feces.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category A/B
Category A/B
Mast Cell Stabilizer
Antihistamine / Mast Cell Stabilizer